Oliver Hatley

1.3k total citations
27 papers, 952 citations indexed

About

Oliver Hatley is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, Oliver Hatley has authored 27 papers receiving a total of 952 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 14 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Oliver Hatley's work include Pharmacogenetics and Drug Metabolism (16 papers), Drug Transport and Resistance Mechanisms (12 papers) and Analytical Chemistry and Chromatography (4 papers). Oliver Hatley is often cited by papers focused on Pharmacogenetics and Drug Metabolism (16 papers), Drug Transport and Resistance Mechanisms (12 papers) and Analytical Chemistry and Chromatography (4 papers). Oliver Hatley collaborates with scholars based in United Kingdom, United States and Germany. Oliver Hatley's co-authors include Amin Rostami‐Hodjegan, Andrés Olivares‐Morales, Christopher R. Jones, Aleksandra Galetin, Бо Лю, Masoud Jamei, Sheila Annie Peters, Anna‐Lena Ungell, David B. Turner and Leon Aarons and has published in prestigious journals such as Pharmaceutical Research, Journal of Pharmaceutical Sciences and Clinical Pharmacology & Therapeutics.

In The Last Decade

Oliver Hatley

23 papers receiving 926 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oliver Hatley United Kingdom	16	324	297	206	206	145	27	952
Aki T. Heikkinen Finland	18	236 0.7×	317 1.1×	215 1.0×	211 1.0×	114 0.8×	34	819
Jianghong Fan United States	20	307 0.9×	357 1.2×	423 2.1×	202 1.0×	195 1.3×	45	1.5k
Kirstin Thelen Germany	20	386 1.2×	324 1.1×	191 0.9×	248 1.2×	259 1.8×	26	1.3k
Pradeep Sharma United Kingdom	20	290 0.9×	468 1.6×	201 1.0×	172 0.8×	259 1.8×	45	1.0k
Kimberley A. Lentz United States	14	125 0.4×	305 1.0×	199 1.0×	323 1.6×	134 0.9×	24	963
Xavier Boulenc France	15	336 1.0×	303 1.0×	198 1.0×	109 0.5×	94 0.6×	19	814
Jingjing Yu United States	12	349 1.1×	306 1.0×	160 0.8×	64 0.3×	198 1.4×	23	852
Ta C. Wu United States	8	301 0.9×	310 1.0×	128 0.6×	168 0.8×	186 1.3×	8	789
Vikash K. Sinha Belgium	11	520 1.6×	338 1.1×	178 0.9×	93 0.5×	91 0.6×	12	878
Viviane Meunier France	8	507 1.6×	396 1.3×	308 1.5×	114 0.6×	102 0.7×	9	1.1k

Countries citing papers authored by Oliver Hatley

Since Specialization

Citations

This map shows the geographic impact of Oliver Hatley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Hatley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Hatley more than expected).

Fields of papers citing papers by Oliver Hatley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Hatley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Hatley. The network helps show where Oliver Hatley may publish in the future.

Co-authorship network of co-authors of Oliver Hatley

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Hatley. A scholar is included among the top collaborators of Oliver Hatley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Hatley. Oliver Hatley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pan, Xian, Katherine L. Gill, Amita Pansari, et al.. (2025). Cytokine Dynamics in Action: A Mechanistic Approach to Assess Interleukin 6 Related Therapeutic Protein‐Drug–Disease Interactions. Clinical Pharmacology & Therapeutics. 117(5). 1369–1380. 1 indexed citations

Braak, Bas ter, Steven J. Kunnen, Barira Islam, et al.. (2025). Transcriptomic changes and mitochondrial toxicity in response to acute and repeat dose treatment with brequinar in human liver and kidney in vitro models. Toxicology in Vitro. 104. 106010–106010.

Yeo, Karen Rowland, Oliver Hatley, Ben G. Small, & Trevor N. Johnson. (2023). Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study. Pharmaceutics. 15(7). 1922–1922. 2 indexed citations

Ezuruike, Udoamaka, et al.. (2023). Exploring the impact of ethnicity on drug pharmacokinetics using PBPK models: A case study with lansoprazole in Japanese subjects. British Journal of Clinical Pharmacology. 91(4). 1016–1030.

Kilford, Peter, Iain Gardner, Oliver Hatley, et al.. (2022). Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator. CPT Pharmacometrics & Systems Pharmacology. 11(7). 822–832. 32 indexed citations

Almond, Lisa M., Alexander Berg, Iain Gardner, et al.. (2021). Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs. CPT Pharmacometrics & Systems Pharmacology. 10(11). 1382–1395. 11 indexed citations

Crowe, Alexandra, Qiang Liu, Sonia Pahwa, et al.. (2020). Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interaction Potential of Vemurafenib Using R-Value and Physiologically-Based Pharmacokinetic Models. Journal of Pharmaceutical Sciences. 110(1). 314–324. 9 indexed citations

Mendes, Maïlys De Sousa, Oliver Hatley, Katherine L. Gill, Karen Rowland Yeo, & Alice Ke. (2020). A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients. European Journal of Pharmaceutical Sciences. 150. 105355–105355. 12 indexed citations

Kim, Yun, Oliver Hatley, Su‐jin Rhee, et al.. (2019). Development of a Korean‐specific virtual population for physiologically based pharmacokinetic modelling and simulation. Biopharmaceutics & Drug Disposition. 40(3-4). 135–150. 16 indexed citations

10.

Terao, Kimio, Katherine L. Gill, Oliver Hatley, et al.. (2019). Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. The AAPS Journal. 21(3). 42–42. 22 indexed citations

11.

Patel, Nikunjkumar, Oliver Hatley, Alexander Berg, et al.. (2018). Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin. The AAPS Journal. 20(3). 47–47. 12 indexed citations

12.

Hatley, Oliver, Christopher R. Jones, Aleksandra Galetin, & Amin Rostami‐Hodjegan. (2017). Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors. Biopharmaceutics & Drug Disposition. 38(3). 187–208. 15 indexed citations

13.

Pahwa, Sonia, Khondoker Alam, Alexandra Crowe, et al.. (2017). Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport. Journal of Pharmaceutical Sciences. 106(8). 2123–2135. 42 indexed citations

14.

Hatley, Oliver, Christopher R. Jones, Aleksandra Galetin, & Amin Rostami‐Hodjegan. (2016). Quantifying gut wall metabolism: methodology matters. Biopharmaceutics & Drug Disposition. 38(2). 155–160. 17 indexed citations

15.

Peters, Sheila Annie, Christopher R. Jones, Anna‐Lena Ungell, & Oliver Hatley. (2016). Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models. Clinical Pharmacokinetics. 55(6). 673–696. 68 indexed citations

16.

Almond, Lisa M., Sophie Mukadam, I. Gardner, et al.. (2016). Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. Drug Metabolism and Disposition. 44(6). 821–832. 91 indexed citations

17.

Jones, Christopher R., Oliver Hatley, Anna‐Lena Ungell, et al.. (2016). Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination. The AAPS Journal. 18(3). 589–604. 43 indexed citations

18.

Heikkinen, Aki T., Arno Friedlein, Mariette Matondo, et al.. (2014). Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine. Pharmaceutical Research. 32(1). 74–90. 45 indexed citations

19.

Kostewicz, Edmund, Leon Aarons, Martin Bergstrand, et al.. (2013). PBPK models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences. 57. 300–321. 241 indexed citations

20.

Olivares‐Morales, Andrés, Oliver Hatley, David B. Turner, et al.. (2013). The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data. Pharmaceutical Research. 31(3). 720–730. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact